These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 32399253

  • 1. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD, Zhao E, Zhu J, Connolly-Strong E, Furie RA.
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [Abstract] [Full Text] [Related]

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 3. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA.
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [Abstract] [Full Text] [Related]

  • 4. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD, Wan GJ, Panaccio MP, Zhao E, Zhu J, Bilyk R, Furie RA.
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [Abstract] [Full Text] [Related]

  • 5. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
    Askanase AD, Furie RA.
    Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
    [Abstract] [Full Text] [Related]

  • 6. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
    Furie RA, Mitrane M, Zhao E, Becker PM.
    Lupus Sci Med; 2017 Jul; 4(1):e000240. PubMed ID: 29344387
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
    Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM.
    Lupus Sci Med; 2016 Jul; 3(1):e000180. PubMed ID: 27933199
    [Abstract] [Full Text] [Related]

  • 8. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD, Wright D, Zhao E, Zhu J, Bilyk R, Furie RA.
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [Abstract] [Full Text] [Related]

  • 10. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [Abstract] [Full Text] [Related]

  • 11. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
    Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, Haier B, Jimenez T, Brittain C, Liu J, Barbey C, Stach C.
    Rheumatology (Oxford); 2021 Nov 03; 60(11):5397-5407. PubMed ID: 33956056
    [Abstract] [Full Text] [Related]

  • 12. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 13. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, Gregan I, Lo KH, Chevrier M, Rose S.
    Arthritis Rheumatol; 2020 May 20; 72(5):761-768. PubMed ID: 31769212
    [Abstract] [Full Text] [Related]

  • 14. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC, Kennedy WP.
    Ann Rheum Dis; 2016 Jan 20; 75(1):196-202. PubMed ID: 26038091
    [Abstract] [Full Text] [Related]

  • 15. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 20; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.
    Ann Rheum Dis; 2016 Feb 20; 75(2):323-31. PubMed ID: 26338095
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C, EMBODY Investigator Group.
    Arthritis Rheumatol; 2017 Feb 20; 69(2):362-375. PubMed ID: 27598855
    [Abstract] [Full Text] [Related]

  • 19. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B, Deshpande G, Gu T, Popelar B, Philbin M, Wan GJ.
    J Med Econ; 2017 Nov 20; 20(11):1170-1177. PubMed ID: 28760047
    [Abstract] [Full Text] [Related]

  • 20. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 20; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.